Patents by Inventor Yasufumi Kikuchi
Yasufumi Kikuchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9493569Abstract: Structural isomers in sc(Fv)2 compositions of anti-human Mpl antibody and humanized anti-human Mpl antibody were separated, and the obtained structural isomers were cleaved at their linkers to confirm that the structural isomers are of single chain diabody type and bivalent scFv type. In addition, the agonistic activities of these structural isomers were revealed to be significantly different. Furthermore, the present inventors discovered that the content ratio of the structural isomers in sc(Fv)2 compositions could be regulated by altering temperature, modifying lengths of the linkers of sc(Fv)2, or amino acids in their variable regions.Type: GrantFiled: March 31, 2006Date of Patent: November 15, 2016Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Hiroyuki Tsunoda, Akiko Koga, Yasufumi Kikuchi
-
Patent number: 8759025Abstract: The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host cells containing said vectors; processes for preparing antibodies comprising the step of culturing said host cells; and therapeutic agents for hematological disorders comprising said antibodies.Type: GrantFiled: December 19, 2011Date of Patent: June 24, 2014Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yasufumi Kikuchi, Shinsuke Uno, Yasuko Kinoshita, Shigeyuki Iijima, Naoshi Fukushima, Masayuki Tsuchiya
-
Publication number: 20120156724Abstract: The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host cells containing said vectors; processes for preparing antibodies comprising the step of culturing said host cells; and therapeutic agents for hematological disorders comprising said antibodies.Type: ApplicationFiled: December 19, 2011Publication date: June 21, 2012Inventors: Yasufumi Kikuchi, Shinsuke Uno, Yasuko Kinoshita, Shigeyuki Iijima, Naoshi Fukushima, Masayuki Tsuchiya
-
Patent number: 8101719Abstract: The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host cells containing said vectors; processes for preparing antibodies comprising the step of culturing said host cells; and therapeutic agents for hematological disorders comprising said antibodies.Type: GrantFiled: November 11, 2004Date of Patent: January 24, 2012Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yasufumi Kikuchi, Shinsuke Uno, Yasuka Kinoshita, Shigeyuki Iijima, Naoshi Fukushima, Masayuki Tsuchiya
-
Publication number: 20110065149Abstract: Described herein is a polynucleotide encoding a fusion protein comprising two or more polypeptide domains and a polypeptide linker joining the domains, wherein the sequence of the polynucleotide encoding the polypeptide linker is selected such that when the mRNA transcribed from the polynucleotide is translated in a host cell transfected with the polynucleotide, the translation rate of the mRNA region encoding the polypeptide linker is slower than the translation rate of the mRNA region encoding the polypeptide domain immediately upstream thereof. Also provided are a vector transfected with the polynucleotide of the present invention so that the polynucleotide can be expressed in the host cell; a host cell transformed by that vector; and a process for producing a fusion protein comprising culturing the host cell, and recovering the fusion protein thus produced.Type: ApplicationFiled: August 21, 2007Publication date: March 17, 2011Applicants: National University Corporation Kobe University, Chugai Seiyaku Kabushiki KaishaInventors: Shigeo Kato, Yoichi Kumada, Tomomi Kawasaki, Yasufumi Kikuchi
-
Patent number: 7696325Abstract: This invention relates to reconstructed polypeptides which have properties of inducing apoptosis of nucleated blood cells having Integrin Associated Protein (IAP) and causing no hemagglutination. The reconstructed polypeptides comprise two or more H chain V regions and two or more L chain V regions of a monoclonal antibody which induces apoptosis of nucleated blood cells having IAP. The reconstructed polypeptides are useful as a therapeutic agent for blood dyscrasia such as leukemia.Type: GrantFiled: March 12, 2001Date of Patent: April 13, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Naoshi Fukushima, Masayuki Tsuchiya, Masayoshi Oh-Eda, Shinsuke Uno, Yasufumi Kikuchi
-
Publication number: 20090297501Abstract: Structural isomers in sc(Fv)2 compositions of anti-human Mpl antibody and humanized anti-human Mpl antibody were separated, and the obtained structural isomers were cleaved at their linkers to confirm that the structural isomers are of single chain diabody type and bivalent scFv type. In addition, the agonistic activities of these structural isomers were revealed to be significantly different. Furthermore, the present inventors discovered that the content ratio of the structural isomers in sc(Fv)2 compositions could be regulated by altering temperature, modifying lengths of the linkers of sc(Fv)2, or amino acids in their variable regions.Type: ApplicationFiled: March 31, 2006Publication date: December 3, 2009Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Hiroyuki Tsunoda, Akiko Koga, Yasufumi Kikuchi
-
Publication number: 20080107654Abstract: The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host cells containing said vectors; processes for preparing antibodies comprising the step of culturing said host cells; and therapeutic agents for hematological disorders comprising said antibodies.Type: ApplicationFiled: November 11, 2004Publication date: May 8, 2008Inventors: Yasufumi Kikuchi, Shinsuke Uno, Yasuko Kinoshita, Shigeyuki Iijima, Naoshi Fukushima, Masayuki Tsuchiya
-
Patent number: 7220828Abstract: The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: GrantFiled: March 10, 1998Date of Patent: May 22, 2007Assignee: Zenyth Operations Pty LtdInventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Jian-Guo Zhang, Alison Farley, Warren Alexander, Steven Rakar, Yasufumi Kikuchi, Tetsuo Kojima, Masatsugu Maeda, Louis Fabri, Andrew Nash
-
Publication number: 20060294608Abstract: The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: ApplicationFiled: August 24, 2006Publication date: December 28, 2006Applicant: Zenyth Operations Pty LtdInventors: Douglas Hilton, Nicos Nicola, Alison Farley, Tracy Willson, Jian-Guo Zhang, Warren Alexander, Steven Rakar, Louis Fabri, Tetsuo Kojima, Masatsugu Maeda, Yasufumi Kikuchi, Andrew Nash
-
Publication number: 20040258684Abstract: Modified antibodies containing 2 or more H chain V domains and or more L chain V domains of a monoclonal antibody which can transduce a signal into cells by crosslinking a cell surface molecule, thereby serving as an agonist. Because of being usable as agonists for signal transduction, these modified antibodies are useful as, for example, preventives and/or remedies for various diseases such as cancer, inflammation, hormone disorders and blood diseases.Type: ApplicationFiled: October 7, 2002Publication date: December 23, 2004Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Naoshi Fukushima, Masayuki Tsuchiya, Masayoshi Oh-eda, Shinsuke Uno, Yasufumi Kikuchi, Toshihiko Ohtomo
-
Publication number: 20040073013Abstract: This invention relates to reconstructed polypeptides which have properties of inducing apoptosis of nucleated blood cells having Integrin Associated Protein (IAP) and causing no hemagglutination. The reconstructed polypeptides comprise two or more H chain V regions and two or more L chain V regions of a monoclonal antibody which induces apoptosis of nucleated blood cells having IAP. The reconstructed polypeptides are useful as a therapeutic agent for blood dyscrasia such as leukemia.Type: ApplicationFiled: October 2, 2002Publication date: April 15, 2004Inventors: Naoshi Fukushima, Masayuki Tsuchiya, Masayoshi Oh-Eda, Shinsuke Uno, Yasufumi Kikuchi
-
Publication number: 20040058393Abstract: Modified antibodies containing 2 or more H chain V domains and or more L chain V domains of a monoclonal antibody which can transduce a signal into cells by crosslinking a cell surface molecule, thereby serving as an agonist. Because of being usable as agonists for signal transduction, these modified antibodies are useful as, for example, preventives and/or remedies for various diseases such as cancer, inflammation, hormone disorders and blood diseases.Type: ApplicationFiled: June 24, 2003Publication date: March 25, 2004Inventors: Naoshi Fukishima, Masayuki Tsuchiya, Masayoshi Oheda, Shinsuke Uno, Yasufumi Kikuchi, Toshihiko Ohtomo
-
Publication number: 20030108546Abstract: This invention relates to Novel single-chain Fvs capable of inducing apoptosis of nucleated blood cells having Integrin Associated Protein (IAP). The single-chain Fvs of the invention comprise an L chain comprising the L chain V region of the mouse monoclonal antibodies capable of inducing apoptosis of cells having human IAP, an H chain comprising the H chain V region of the mouse monoclonal antibodies capable of inducing apoptosis of cells having human IAP and a linker connecting them. The single-chain Fvs of the invention are useful as a therapeutic agent for blood dyscrasia such as leukemia.Type: ApplicationFiled: May 6, 2002Publication date: June 12, 2003Applicant: Chugai Seiyaku kabushiki kaishaInventors: Naoshi Fukushima, Shinsuke Uno, Masayoshi Oh-Eda, Yasufumi Kikuchi